GLP Watchdog

Effecty vs Verge

Neither Effecty nor Verge has an FDA warning letter on record. On compounded tirzepatide injection, Effecty costs $420 less a year at standing rates: $235 a month against $270 a month at Verge.

By Ruth Calder · Enforcement Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed

The record

Effecty / Verge

Effecty logo

Effecty

8.1/10

Verge logo

Verge

8.1/10

FDA warning letters
None on record
None on record
Pharmacy
None named in our record
None named in our record
Lowest standing price
$170/moCompounded semaglutide injection
$170/moCompounded semaglutide injection
States
All 50 states
All 50 states
Checked
Prices captured Record checked October 2026
Prices captured Record checked October 2026
Visit EffectyFull review
Visit VergeFull review

Neither Effecty nor Verge pays us. Links to them earn nothing. Scores: Effecty 8.1, Verge 8.1. How we are paid

What the record shows

  1. 01

    Neither Effecty nor Verge has an FDA warning letter on record.

  2. 02

    Neither names the pharmacy that compounds its medication.

  3. 03

    On compounded tirzepatide injection, Effecty costs $420 less a year at standing rates: $235 a month against $270 a month at Verge.

  4. 04

    Only Effecty lists a price for brand-name semaglutide pen and brand-name tirzepatide pen.

  5. 05

    Effecty does not state its cancellation terms; Verge states you can cancel at any time.

Prices and terms, product by product

A price is set against the other side only for the same product, and only when both are standing monthly or 4-week rates. Those pairs are compared by yearly cost.

Effecty

Verge

Compounded semaglutide injection

$170/mo

$2,040 a year

$170/mo

$2,040 a year

Compounded tirzepatide injection

$235/moLower

$2,820 a year

$270/mo

$3,240 a year

Brand-name semaglutide pen

$1,300/mo

$15,600 a year

Not sold or not priced
Brand-name tirzepatide pen

$1,300/mo

$15,600 a year

Not sold or not priced
Price includes
Medication, clinician visits, shipping
Medication, clinician visits, shipping
Cancel any time
Not stated
Yes, stated
Minimum term
Month-to-month plan has none; longer plans are paid in advance
None on one-time orders; subscriptions renew every 25 days (1-month) or 80 days (3-month) until canceled
Refunds
No refunds of subscription fees already paid; all sales are final
"We cannot accept returns of prescription products for reuse or resale, and all sales are final." A declined patient's card hold is released.

Read off each seller’s own pages. Effecty: October 17, 2026. Verge: October 17, 2026. Every plan and dose we hold is on the full review.

The case for each

The case for Effecty

8.1/10
  • $420 a year less on compounded tirzepatide injection
  • Sells brand-name semaglutide pen and brand-name tirzepatide pen, which Verge does not price
  • Names no compounding pharmacy
Visit Effecty

The case for Verge

8.1/10
  • States you can cancel at any time
  • Names no compounding pharmacy
Visit Verge

Scores

Effecty 8.1 · Verge 8.1 out of 10. Six weighted parts.

Value25%

6.1A
vs
B
6.1

Effectiveness25%

10.0A
vs
B
10.0

User Experience15%

8.0A
vs
B
8.0

Trust & Safety15%

7.5A
vs
B
7.5

Accessibility10%

10.0A
vs
B
10.0

Support10%

7.0A
vs
B
7.0

The score is the same formula for every seller. Payment does not enter it. Method

Effecty vs Verge: questions

Neither Effecty nor Verge has an FDA warning letter on record. Letters are matched to a seller by company, domain and address, never by a similar name.
Neither names the pharmacy that compounds its medication.
Effecty, by $420 a year at standing rates. Effecty: $235 a month, about $2,820 a year. Verge: $270 a month, about $3,240 a year.
Effecty does not state its cancellation terms. Verge states you can cancel at any time; refunds: "we cannot accept returns of prescription products for reuse or resale, and all sales are final." a declined patient's card hold is released.
Neither Effecty nor Verge pays us. Links to them earn nothing. Scores: Effecty 8.1, Verge 8.1.

Other sellers we are paid by

Affiliate partners outside this pair. Each has its own record and review, scored the same way.

Sellers closest to these two

Matched on molecule, form and price. Every pair we list · The register

Brand names on this page are registered marks. Novo Nordisk holds Wegovy®, Ozempic® and Rybelsus®; Eli Lilly holds Zepbound®, Mounjaro® and Foundayo®. Neither company has any tie to GLP Watchdog. Trademarks